Suchergebnisse - "Gebhart, Géraldine"

PubPharm (28)

1

Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial

enthalten in: Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 2024

von Gebhart, G. | Keyaerts, M. | Guiot, T. | +23

2

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain) : a randomised, open-label, phase 2 trial

enthalten in: Lancet (London, England) | 2024

von Pérez-García, J. | Cortés, J. | Ruiz-Borrego, M. | +27

3

Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer : RESPONSE, a substudy of the randomized PHERGain trial

enthalten in: European journal of nuclear medicine and molecular imaging | 2024

von Llombart-Cussac, A. | Prat, A. | Pérez-García, J. | +18

4

Molecular Imaging in Breast Cancer : Martine Piccart and Géraldine Gebhart Talk with David Mankoff About 2 Generations of Research

enthalten in: Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 2024

von Gebhart, G. | Piccart, M. | Mankoff, D.

5

Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial)

enthalten in: NPJ breast cancer | 2024

von Mileva, M. | de Vries, E. | Guiot, T. | +17

6

18F-FDG PET "Metabolic Response" to Neoadjuvant Systemic Therapy for Breast Cancer : Quo Vadis?

enthalten in: Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 2023

von Gebhart, G.

CommentOn: J Nucl Med. 2023 Nov;64(11):1690-1696. - PMID 37652539

7

18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Iqbal, R. | Yaqub, M. | Bektas, H. | +10

CommentIn: Clin Cancer Res. 2023 Jun 1;29(11):2015-2016. - PMID 36988617

8

PIK3CA copy-number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer

enthalten in: Cold Spring Harbor molecular case studies | 2023

von Amato, O. | Buisseret, L. | Gebhart, G. | +5

9

Author Correction : FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer

enthalten in: NPJ breast cancer | 2022

von Gombos, A. | Venet, D. | Ameye, L. | +14

ErratumFor: NPJ Breast Cancer. 2021 Sep 21;7(1):125. - PMID 34548493

10

Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant

enthalten in: European journal of cancer (Oxford, England : 1990) | 2022

von Malorni, L. | Tyekucheva, S. | Hilbers, F. | +32